PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 146 filers reported holding PUMA BIOTECHNOLOGY INC in Q3 2019. The put-call ratio across all filers is 1.51 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $121,000 | -80.0% | 11,900 | -79.4% | 0.00% | -75.0% |
| Q2 2020 | $604,000 | +24.8% | 57,900 | +1.0% | 0.01% | 0.0% |
| Q1 2020 | $484,000 | +1.3% | 57,300 | +1.1% | 0.01% | +60.0% |
| Q4 2019 | $478,000 | -22.8% | 56,700 | -1.4% | 0.01% | -28.6% |
| Q3 2019 | $619,000 | -15.3% | 57,500 | 0.0% | 0.01% | -12.5% |
| Q2 2019 | $731,000 | -67.8% | 57,500 | -1.8% | 0.01% | -68.0% |
| Q1 2019 | $2,271,000 | +89.4% | 58,534 | -0.6% | 0.02% | +66.7% |
| Q4 2018 | $1,199,000 | -55.6% | 58,900 | 0.0% | 0.02% | -42.3% |
| Q3 2018 | $2,701,000 | +4478.0% | 58,900 | +5790.0% | 0.03% | +2500.0% |
| Q2 2018 | $59,000 | -13.2% | 1,000 | 0.0% | 0.00% | 0.0% |
| Q1 2018 | $68,000 | -31.3% | 1,000 | 0.0% | 0.00% | 0.0% |
| Q4 2017 | $99,000 | -17.5% | 1,000 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $120,000 | +37.9% | 1,000 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $87,000 | +8600.0% | 1,000 | +33233.3% | 0.00% | – |
| Q4 2015 | $1,000 | -100.0% | 3 | -100.0% | 0.00% | -100.0% |
| Q1 2015 | $3,011,000 | -6.9% | 12,753 | -25.4% | 0.03% | -8.1% |
| Q4 2014 | $3,235,000 | – | 17,089 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Cormorant Asset Management, LP | 207,500 | $21,609,000 | 4.97% |
| WEATHERBIE CAPITAL, LLC | 250,296 | $26,066,000 | 2.47% |
| Redmile Group, LLC | 172,092 | $17,922,000 | 2.14% |
| Tekla Capital Management LLC | 185,820 | $19,351,000 | 1.93% |
| Iguana Healthcare Management, LLC | 35,000 | $3,645,000 | 1.68% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 5,686,668 | $592,210,000 | 1.62% |
| Atika Capital Management LLC | 11,350 | $1,182,000 | 1.01% |
| Eventide Asset Management | 44,900 | $4,676,000 | 0.73% |
| Ghost Tree Capital, LLC | 11,330 | $1,180,000 | 0.70% |
| BB BIOTECH AG | 117,991 | $12,288,000 | 0.63% |